Effect of Prebiotic on Microbiota, Intestinal Permeability, and Glycemic Control in Children With Type 1 Diabetes.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 10 2019
Historique:
received: 27 02 2019
accepted: 06 06 2019
pubmed: 13 6 2019
medline: 30 5 2020
entrez: 13 6 2019
Statut: ppublish

Résumé

Patients with type 1 diabetes (T1D) have lower microbiota diversity and distinct gut microbial profiles that have been linked to changes in intestinal permeability. Prebiotics are nondigestible carbohydrates that alter gut microbiota and could potentially improve glycemic control and reduce intestinal permeability and thereby insulin sensitivity. To determine the effect of prebiotics on glycemic control, gut microbiota, and intestinal permeability in children with T1D. A randomized, placebo-controlled trial in children 8 to 17 years of age with T1D using placebo or prebiotic oligofructose-enriched inulin for 12 weeks. Baseline, 3-month, and 6-month assessments included HbA1c, C-peptide, gut microbiota, intestinal permeability, frequency of diabetic ketoacidosis (DKA), and severe hypoglycemia. Forty-three subjects were randomized and 38 completed the study. The groups were similar at baseline: prebiotic (N = 17), age 12.5 years (SD of 2.8), HbA1c 8.02% (SD of 0.82); placebo (N = 21), age 12.0 years (SD of 2.6), HbA1c 8.08% (SD of 0.91). No significant differences were found in the frequency of DKA or severe hypoglycemia. At 3-months, C-peptide was significantly higher (P = 0.029) in the group who received prebiotics, which was accompanied by a modest improvement in intestinal permeability (P = 0.076). There was a significant increase in the relative abundance of Bifidobacterium within the prebiotic group at 3 months that was no longer present after the 3-month washout. The placebo group had significantly higher relative abundance of Streptococcus, Roseburia inulinivorans, Terrisporobacter, and Faecalitalea compared with the prebiotic group at 3 months. Prebiotics are a potentially novel, inexpensive, low-risk treatment addition for T1D that may improve glycemic control. Further larger-scale trials are needed.

Identifiants

pubmed: 31188437
pii: 5513497
doi: 10.1210/jc.2019-00481
doi:

Substances chimiques

Blood Glucose 0
Prebiotics 0

Banques de données

ClinicalTrials.gov
['NCT02442544']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4427-4440

Informations de copyright

Copyright © 2019 Endocrine Society.

Auteurs

Josephine Ho (J)

Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Alissa C Nicolucci (AC)

Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Heidi Virtanen (H)

Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Alana Schick (A)

International Microbiome Centre, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Jon Meddings (J)

Department of Internal Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Raylene A Reimer (RA)

Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.

Carol Huang (C)

Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH